EGFR Tyrosine Kinase Inhibitors As First-line Therapy in Advanced EGFR Mutation-positive Non-small Cell Lung Cancer: Strategies to Improve Clinical Outcome

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2017 Dec 23

PMID 29268473

Citations 6

Authors

Andreas Tiefenbacher

Robert Pirker

Affiliations

Soon will be listed here.

Citing Articles

Design and investigation of interactions of novel peptide conjugates of purine and pyrimidine derivatives with EGFR and its mutant T790M/L858R: an in silico and laboratory study.

Hunt H, Goncalves B, Biggs M, Rico M, Murray M, Lebedenko C Mol Divers. 2024; 28(6):3683-3711.

PMID: 38240950 DOI: 10.1007/s11030-023-10772-x.

Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer.

Xu C, Yao X, Li T, Wang J, An B, Wang J Transl Cancer Res. 2022; 9(4):2875-2883.

PMID: 35117644 PMC: 8797611. DOI: 10.21037/tcr.2020.02.28.

Zebrafish Avatars towards Personalized Medicine-A Comparative Review between Avatar Models.

Costa B, Estrada M, Mendes R, Fior R Cells. 2020; 9(2).

PMID: 31991800 PMC: 7072137. DOI: 10.3390/cells9020293.

Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report.

Cimpeanu E, Ahmed J, Zafar W, DeMarinis A, Bardarov S, Salman S World J Clin Cases. 2020; 8(1):97-102.

PMID: 31970174 PMC: 6962068. DOI: 10.12998/wjcc.v8.i1.97.

Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives.

Tiefenbacher A, Pirker R Memo. 2018; 11(2):112-115.

PMID: 29983826 PMC: 6006273. DOI: 10.1007/s12254-018-0408-y.

References

Wei L, Kuo M, Chen C, Chou C, Lai K, Lee C . Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003; 22(10):1517-27. DOI: 10.1038/sj.onc.1206226. View

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V . Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009; 27(8):1227-34. DOI: 10.1200/JCO.2007.14.5466. View

Pirker R, Pereira J, Szczesna A, von Pawel J, Krzakowski M, Ramlau R . Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373(9674):1525-31. DOI: 10.1016/S0140-6736(09)60569-9. View

Oxnard G, Arcila M, Sima C, Riely G, Chmielecki J, Kris M . Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2010; 17(6):1616-22. PMC: 3060283. DOI: 10.1158/1078-0432.CCR-10-2692. View

Fan W, Tang Z, Yin L, Morrison B, Hafez-Khayyata S, Fu P . MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res. 2011; 71(13):4494-505. PMC: 3132557. DOI: 10.1158/0008-5472.CAN-10-2668. View

Pirker R, Pereira J, von Pawel J, Krzakowski M, Ramlau R, Park K . EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2011; 13(1):33-42. DOI: 10.1016/S1470-2045(11)70318-7. View

Dearden S, Stevens J, Wu Y, Blowers D . Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013; 24(9):2371-6. PMC: 3755331. DOI: 10.1093/annonc/mdt205. View

Pujol J, Pirker R, Lynch T, Butts C, Rosell R, Shepherd F . Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer. 2013; 83(2):211-8. DOI: 10.1016/j.lungcan.2013.11.006. View

10.

Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y . Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014; 15(11):1236-44. DOI: 10.1016/S1470-2045(14)70381-X. View

11.

Pirker R . What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?. Future Oncol. 2015; 11(1):153-67. DOI: 10.2217/fon.14.178. View

12.

Pirker R . Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update. Curr Opin Oncol. 2015; 27(2):87-93. DOI: 10.1097/CCO.0000000000000162. View

13.

Thatcher N, Hirsch F, Luft A, Szczesna A, Ciuleanu T, Dediu M . Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015; 16(7):763-74. DOI: 10.1016/S1470-2045(15)00021-2. View

14.

Pirker R . Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2016; 28(2):115-21. DOI: 10.1097/CCO.0000000000000260. View

15.

Mok T, Wu Y, Ahn M, Garassino M, Kim H, Ramalingam S . Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2016; 376(7):629-640. PMC: 6762027. DOI: 10.1056/NEJMoa1612674. View

16.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S . Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2017; 5(5):435-444. DOI: 10.1016/S2213-2600(17)30129-7. View

17.

Herbst R, Redman M, Kim E, Semrad T, Bazhenova L, Masters G . Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2017; 19(1):101-114. PMC: 5847342. DOI: 10.1016/S1470-2045(17)30694-0. View